Phase 2: Systematic Reintroduction Reintroduce one food group every three days while monitoring symptoms to identify personal tolerance levels and create a sustainable, personalized diet plan
A 2025 article from SHRM reports a notable increase in the average representation of GLP-1 drugs used for weight loss in total annual claims for employers, increasing from 8.9 percent in 2024 to 10.5 percent in 2025
Cardiovasc Diabetol 17(1):5 Denic A, Mathew J, Lerman LO, Lieske JC, Larson JJ, Alexander MP et al (2017) Single-nephron glomerular filtration rate in healthy adults
GLP-1 weight loss injections such as Ozempic and Mounjaro can cost hundreds of dollars a month without health insurance coveragewhich seems steep for a drug that mimics a hormone your body makes naturally
In the future, with the in-depth exploration of the mechanism of GLP-1R action and the development of multi-target agonists (e.g., GLP-1R/GIPR dual agonists), GLP-1R-related therapeutics are expected to make breakthroughs in a wider range of disease areas (e.g., nonalcoholic steatohepatitis, AD, etc.), providing a more precise and highly effective strategy for the treatment of metabolic diseases and related complications
